Table 4 The starting dose of PCSK9 inhibitors
Alirocumab | ||||
|---|---|---|---|---|
LDL target non-achiever N = 73 | LDL target achiever N = 82 | P value | ||
75 mg Q2W | 62 (84.9) | 140Â mg Q2W | 69 (84.2) | 1.000 |
75 mg Q3W to Q4W | 9 (12.3) | 140Â mg Q3W to Q4W | 13 (15.9) | 0.691 |
150 mg Q4W | 0 (0.0) | 420Â mg Q4W | 0 (0.0) | 0.000 |
*Others | 2 (2.7) | Others | 0 (0.0) | 0.000 |
Evolocumab | ||||
|---|---|---|---|---|
LDL target non-achiever N = 18 | LDL target achiever N = 38 | P value | ||
75 mg Q2W | 11 (61.1) | 140 mg Q2W | 29 (76.3) | 0.390 |
75 mg Q3W to Q4W | 3 (16.7) | 140 mg Q3W to Q4W | 2 (5.3) | 0.314 |
140 mg Q4W | 3 (3.3) | 420 mg Q4W | 2 (5.3) | 0.314 |
*Others | 1 (5.6) | Others | 5 (13.2) | 0.652 |